Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Trastuzumab + Paclitaxel in HER2+ MBC
NCT01306942Phase 2Completed
- Sponsor
- GEICAM
- Start
- Jul 2011
- Primary completion
- Dec 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in breast cancer, sponsored by GEICAM. Started Jul 2011; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01306942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306942.